The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia

The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström’s Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease. Second-generation BTK inhibitors are being used and studied to improve clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ababneh, Obada, Abushukair, Hassan, Qarqash, Aref, Syaj, Sebawe, Al Hadidi, Samer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358782/
https://www.ncbi.nlm.nih.gov/pubmed/35950210
http://dx.doi.org/10.1007/s44228-022-00007-5
_version_ 1784764003740811264
author Ababneh, Obada
Abushukair, Hassan
Qarqash, Aref
Syaj, Sebawe
Al Hadidi, Samer
author_facet Ababneh, Obada
Abushukair, Hassan
Qarqash, Aref
Syaj, Sebawe
Al Hadidi, Samer
author_sort Ababneh, Obada
collection PubMed
description The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström’s Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease. Second-generation BTK inhibitors are being used and studied to improve clinical outcomes and/or safety profile. Zanubrutinib, one such second-generation inhibitor, was recently approved in treatment-naive and refractory/relapsed patients. Here, we review the use of BTK inhibitors in WM in front-line and refractory or relapsed settings. We also highlight common adverse events, the emergence of BTK inhibitors resistance, and future directions of their use.
format Online
Article
Text
id pubmed-9358782
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-93587822022-08-09 The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia Ababneh, Obada Abushukair, Hassan Qarqash, Aref Syaj, Sebawe Al Hadidi, Samer Clin Hematol Int Review Article The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström’s Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease. Second-generation BTK inhibitors are being used and studied to improve clinical outcomes and/or safety profile. Zanubrutinib, one such second-generation inhibitor, was recently approved in treatment-naive and refractory/relapsed patients. Here, we review the use of BTK inhibitors in WM in front-line and refractory or relapsed settings. We also highlight common adverse events, the emergence of BTK inhibitors resistance, and future directions of their use. Springer Netherlands 2022-05-23 /pmc/articles/PMC9358782/ /pubmed/35950210 http://dx.doi.org/10.1007/s44228-022-00007-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Ababneh, Obada
Abushukair, Hassan
Qarqash, Aref
Syaj, Sebawe
Al Hadidi, Samer
The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
title The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
title_full The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
title_fullStr The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
title_full_unstemmed The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
title_short The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
title_sort use of bruton tyrosine kinase inhibitors in waldenström’s macroglobulinemia
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358782/
https://www.ncbi.nlm.nih.gov/pubmed/35950210
http://dx.doi.org/10.1007/s44228-022-00007-5
work_keys_str_mv AT ababnehobada theuseofbrutontyrosinekinaseinhibitorsinwaldenstromsmacroglobulinemia
AT abushukairhassan theuseofbrutontyrosinekinaseinhibitorsinwaldenstromsmacroglobulinemia
AT qarqasharef theuseofbrutontyrosinekinaseinhibitorsinwaldenstromsmacroglobulinemia
AT syajsebawe theuseofbrutontyrosinekinaseinhibitorsinwaldenstromsmacroglobulinemia
AT alhadidisamer theuseofbrutontyrosinekinaseinhibitorsinwaldenstromsmacroglobulinemia
AT ababnehobada useofbrutontyrosinekinaseinhibitorsinwaldenstromsmacroglobulinemia
AT abushukairhassan useofbrutontyrosinekinaseinhibitorsinwaldenstromsmacroglobulinemia
AT qarqasharef useofbrutontyrosinekinaseinhibitorsinwaldenstromsmacroglobulinemia
AT syajsebawe useofbrutontyrosinekinaseinhibitorsinwaldenstromsmacroglobulinemia
AT alhadidisamer useofbrutontyrosinekinaseinhibitorsinwaldenstromsmacroglobulinemia

Ejemplares similares